Servier Portugal

What Servier Portugal does

Servier Portugal — legally SERVIER PORTUGAL – ESPECIALIDADES FARMACÊUTICAS, LDA. (NIPC 502177420) — is the Portuguese sales and marketing subsidiary of the Servier Group, a French international pharmaceutical company headquartered in Suresnes, France and governed by a non-profit foundation. The Group's activity in Portugal dates to 1964, with the subsidiary formally established in 1978; the Portuguese entity is headquartered at Torre Oriente, Av. Colégio Militar 37F, Lisbon, and employs approximately 150 people.

Servier Portugal markets a portfolio of approximately 43 branded and generic pharmaceutical products organized across four therapeutic verticals: cardiometabolism (hypertension, dyslipidemia, diabetes, heart failure), venous disease (chronic venous disease and hemorrhoidal disease, including the Daflon brand), neurosciences (depression), and oncology (colorectal, gastric, pancreatic cancers and leukemias). Underlying capabilities include pharmaceutical R&D supported at the group level (the Servier Paris-Saclay Research Institute, inaugurated 2023, with 1,500 staff across 45,000 sqm) and 13 global production factories, with approximately 20% of branded drug revenue reinvested into R&D. At the Portuguese level, the company layers digital engagement assets onto its pharmaceutical offering: the MyServier healthcare-professional portal, the Pharmacy Academy (accredited online courses for pharmacists by the Ordem dos Farmacêuticos), dedicated brand sites for Daflon and emoflon, the Insuficiência Cardíaca patient education site, and the SHAPE patient support program for metastatic digestive cancer.

The business model is prescription pharmaceutical sales distributed through Portuguese pharmacy networks (consumer/SMB channel for retail and OTC products such as Daflon) and direct-to-institution sales to hospitals and clinics for specialty medications including oncology. Servier Portugal does not publicly disclose drug pricing. Marketing reach is delivered through content platforms, accredited professional education, and CSR initiatives (e.g., the Bosque dos Corações reforestation with Normas Verdes and ICNF), and the entity has been recognized as Top Employer Portugal (2022, 2023) and Great Place to Work (2025).

Name

Servier Portugal

Legal name

SERVIER PORTUGAL – ESPECIALIDADES FARMACÊUTICAS, LDA.

Website

https://servier.pt

Company type

Private

Founded year

1978

Operating status

Operating

Short description

Servier Portugal is the Portuguese subsidiary of the Servier Group, a non-profit foundation-governed pharmaceutical company. It markets approximately 43 branded and generic medications across cardiometabolic, venous, oncological, and neurological therapeutic areas to patients and healthcare providers in Portugal.

Ownership category

akta.pro rank

Product category

Pharmaceutical Products

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro industry

PRIMARYHLAIAAAB

Specialty Care Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

SECONDARYHLAIAAAE

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

SECONDARYHLAIACAG

Cardiology & Vascular Specialty Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Specialty Pharmaceuticals

Keywords

• Pharmaceutical medications
• Cardiometabolic therapies
• Oncology treatments
• Venous disease drugs
• Healthcare professional education

Headquarters

HQ city

Lisbon

HQ country

Portugal

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

1. Pharmaceutical Sales: Servier generates revenue primarily through the sale of branded and generic pharmaceutical products. The company achieved €6.9 billion in revenue in 2024/25 and invests over 20% of branded drug revenue in R&D.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

Servier Portugal develops, markets, and distributes branded pharmaceutical medications in cardiometabolic, venous, gastrointestinal, metabolic, psychiatric, and oncological therapeutic areas across Portugal. The subsidiary sells a portfolio of approximately 43 distinct products with multiple dosage strengths, distributes them through pharmacy networks and healthcare institutions, and supports healthcare professionals via digital platforms including the MyServier portal, the Pharmacy Academy, and dedicated brand websites for Daflon and emoflon.

Product overview

Servier Portugal operates as the Portuguese subsidiary of the Servier Group, an independent international pharmaceutical company governed by a non-profit foundation. The company offers a comprehensive portfolio of branded medications organized across four therapeutic areas: Cardiometabolism (cardiovascular, hypertension, dyslipidemia, diabetes), Venous Disease (chronic venous disease and hemorrhoidal disease), Neurosciences (depression), and Oncology (colorectal, gastric, pancreatic cancers, cholangiocarcinoma, and leukemias). The portfolio includes approximately 43 distinct products with multiple dosage strengths. In addition to pharmaceutical products, Servier Portugal provides digital platforms and patient/professional resources including the MyServier healthcare professional portal, Pharmacy Academy (accredited online courses for pharmacists), and dedicated product websites for Daflon® and emoflon®, along with patient education resources for heart failure management.

Differentiator

Problem solved

Functional benefit

Brands

• MyServier: Portal dedicated to healthcare professionals providing articles, videos, podcasts, and scientific content on hypertension, dyslipidemia, venous disease, heart failure, and oncology.
• Daflon
• emoflon
• Pharmacy Academy
• Insuficiência Cardíaca

Products and services

• MyServier A dedicated healthcare professional portal offering scientific content including articles, videos, and podcasts organized by therapeutic areas (venous disease, hypertension, cardiovascular risk, heart failure, and oncology) to support clinical practice.
• Pharmacy Academy Online courses for pharmacists in Portugal, with courses credited by the Ordem dos Farmacêuticos (Pharmaceutical Society), providing continuing education in therapeutic areas.
• Daflon® A venoactive medication indicated for treatment of symptoms related to venous insufficiency (heavy legs, pain, tiredness, edema) and symptomatic treatment of hemorrhoidal crisis.
• emoflon® A rectal ointment indicated for treatment of symptoms associated with Hemorrhoidal Disease and its complications.
• Insuficiência Cardíaca (Heart Failure) patient education website Patient-focused website providing accessible information about heart failure management, helping patients understand how to live well with the condition and maintain appropriate care and support.
• Cardiometabolic and oncology pharmaceutical portfolio Branded pharmaceutical medications across four therapeutic areas—cardiometabolism (hypertension, dyslipidemia, diabetes), venous disease, neurosciences (depression), and oncology (colorectal, gastric, pancreatic cancers, cholangiocarcinoma, and leukemias)—including approximately 43 distinct products with multiple dosage strengths.

Quantifiable outcome

• 40% of patients in Portugal do not consistently follow their medication regimen (adherence challenge)
• +2 more outcomes

Named customers3 records

Segments6 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Servier Paris-Saclay Research InstitutecoreStrategic or Co-development Partner · 1 January 2023Servier's dedicated research institute in Paris-Saclay, inaugurated in 2023, spans 45,000 square meters and houses 1,500 employees. The institute enables agile, open approach to R&D centered on patients to accelerate discovery of innovative therapeutic solutions.
• Normas VerdesminorOthersEnvironmental company specializing in sustainable reforestation, responsible for site preparation and planting of maritime pines in the Pinhal de Leiria under ICNF supervision as part of the 'Bosque dos Corações' CSR project.
• ICNF (Instituto da Conservação da Natureza e Florestas)minorOthersGovernmental nature conservation and forestry institute supervising the 'Bosque dos Corações' reforestation project.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• AstraZeneca Portugal: Portuguese subsidiary of AstraZeneca PLC, with strong cardiometabolic (e.g., dapagliflozin), oncology, and respiratory franchises, competing with Servier in heart failure, hypertension, and oncology across Portuguese NHS and hospital channels.
• BIAL – Portela & Cª, S.A. Portugal's largest independent pharmaceutical company, headquartered near Porto, with branded specialty pharma in central nervous system, cardiovascular, and allergy therapeutics, plus a growing R&D footprint — the closest independent Portuguese peer to Servier Portugal in scale, therapeutic focus, and corporate philosophy.
• Novartis Portugal: Portuguese affiliate of Novartis AG, with established cardiology (Entresto heart-failure franchise) and oncology portfolios that compete head-to-head with Servier's cardiometabolic and oncology products in Portuguese NHS tenders.
• Sanofi Portugal: Portuguese affiliate of Sanofi, with deep cardiometabolic (including diabetes), rare disease, and oncology franchises, competing with Servier across hypertension, dyslipidemia, and oncology while pursuing digital health and patient-support programs.
• Merck Sharp & Dohme (MSD) Portugal: Portuguese affiliate of Merck & Co., Inc. with oncology, vaccines, and cardiometabolic offerings that compete with Servier Portugal across hospital and retail channels, particularly in oncology and chronic disease management.
• Boehringer Ingelheim Portugal: Portuguese subsidiary of the family-owned German pharma group; cardiometabolic, respiratory, and specialty focus (e.g., empagliflozin) makes it a direct competitor in hypertension, heart-failure, and diabetes — and a structural parallel as an independent, non-publicly-listed pharma group.
• Roche Portugal: Portuguese subsidiary of F. Hoffmann-La Roche AG with deep oncology and specialty care focus, including colorectal and gastric cancer therapies — directly comparable to Servier's oncology presence and a key hospital-channel competitor.
• Pfizer Portugal: Portuguese subsidiary of Pfizer Inc., offering overlapping cardiovascular, oncology, and specialty portfolios; competes with Servier in Portuguese hospitals and retail pharmacy channels and is a global benchmark for cardiometabolic and oncology pipeline depth.
• GlaxoSmithKline (GSK) Portugal: Portuguese subsidiary of GSK plc with established specialty, vaccines, and respiratory portfolios, overlapping Servier in hospital and pharmacy channels; comparable multinational pharma subsidiary structure and primary-care detailing model.
• Bayer Portugal: Portuguese subsidiary of Bayer AG with overlapping cardiovascular, venous, and consumer-health franchises (including established venoactive and antithrombotic brands), competing directly with Daflon and Servier's CV portfolio in Portuguese hospitals and pharmacies.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/servierportugal

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Servier Portugal